

## Data Sheet

### Plasmid #32

SKU No.: 02-1032

<b>Description</b>	Plasmid #32 enables target proteins to be labeled with an uncleavable N-terminal His8 and a cleavable C-terminal CL7 tag.
<b>Expression</b>	Transcription is induced with IPTG and driven by the T7 RNA polymerase. The plasmid is designed for expression in E. Coli.
<b>Affinity Tag</b>	The C-terminal CL7 tag is downstream of three PreScission protease (PSC) and one Sortase A (SRT) cleavage site.
<b>Cleavage Site(s)</b>	An N-terminal SUMO cleavage site exists upstream of the His8 tag. One SRT and three PSC cleavage sites exist between the target protein and the CL7 tag.
<b>Other Tags</b>	Plasmid #32 includes N-terminal Trx and His8 tags.
<b>Resistance</b>	Kanamycin
<b>Form</b>	100 ng, dissolved in H <sub>2</sub> O.
<b>Concentration</b>	30 ng/μL
<b>Stability</b>	12 months after shipping
<b>Storage</b>	-20° C
<b>Shipping</b>	Room temperature

### Scheme

1. HindIII/SpeI Insertion Site – Trx | SUMO | His8 | Gene of Interest | SRT | PSC | PSC | PSC | CL7

This insertion scheme results in 16 extra aa (including His8 tag) at the N terminus of the target following SUMO protease cleavage.

2. KpnI/SpeI Insertion Site – Trx | SUMO | His8 | Gene of Interest | SRT | PSC | PSC | PSC | CL7

This insertion scheme results in 11 extra aa (including His8 tag) at the N terminus of the target following SUMO protease cleavage.

3. Bsu36I/SpeI Insertion Site – Trx | SUMO | Gene of Interest | SRT | PSC | PSC | PSC | CL7

This insertion scheme maintains the Gene of Interest's wildtype sequence, without adding any extra residues. The N-terminus of the Gene of Interest must include the following to complete the SUMO C-terminal sequence:

P E D L D M E D N D I I E A H R E Q I G G  
**CCTGAGG**ATCTGGACATGGAAGACAATGACATTATCGAAGCTCATCGTGAACAGATTGGTGGT<Gene of Interest>  
*Bsu36I*

You can download the full protocol from <https://trialtusbioscience.com/products/#protocols>.

**For research use only.  
Not for diagnostic or therapeutic use.**

### **Licensing Information**

TriAltus Bioscience holds the exclusive, worldwide license to the CL7 protein purification technology platform. It was licensed from the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, USA. An international patent filing has been made with protection being sought in the United States, Europe, and other major markets. The CL7 purification technology is available for research use. For commercial use or resale, contact us at [sales@trialtusbioscience.com](mailto:sales@trialtusbioscience.com) to discuss commercial licensing.

### **Trademarks**

The Company name, the terms "TriAltus" and "TriAltus Bioscience", the Company logo, and all related names, logos, product and service names, designs, and slogans are trademarks of the Company or its affiliates or licensors. You must not use such marks without the prior written permission of the Company. All other names, logos, product and service names, designs, and slogans on this Website are the trademarks of their respective owners.

Version: 1.0  
Revision Date: 11/20/2019